Xilio Therapeutics, Inc. — Investor Relations & Filings

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes a proprietary, clinically validated platform to engineer biologics, including antibodies, masked bispecifics, and T cell engagers. These molecules are designed to be 'masked' or inactive in systemic circulation and become fully active only within the tumor microenvironment. This approach aims to concentrate the therapeutic effect precisely on the tumor, thereby minimizing systemic toxicity and improving the efficacy-to-toxicity ratio of potent immunotherapies. Xilio's pipeline consists of multiple clinical and preclinical programs designed to deliver powerful cancer treatments to a broader patient population.